Axsome Therapeutics (NASDAQ:AXSM) Earns Buy Rating from Analysts at Deutsche Bank Aktiengesellschaft

Deutsche Bank Aktiengesellschaft assumed coverage on shares of Axsome Therapeutics (NASDAQ:AXSM) in a research report report published on Tuesday morning, Marketbeat.com reports. The brokerage issued a buy rating and a $176.00 target price on the stock.

Other equities research analysts have also recently issued reports about the company. William Blair reaffirmed an “outperform” rating on shares of Axsome Therapeutics in a research note on Friday, January 24th. Truist Financial upped their price target on Axsome Therapeutics from $180.00 to $190.00 and gave the stock a “buy” rating in a research note on Monday, February 3rd. StockNews.com raised Axsome Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, November 20th. Royal Bank of Canada reissued an “outperform” rating and issued a $139.00 target price on shares of Axsome Therapeutics in a research note on Wednesday, January 29th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $121.00 target price on shares of Axsome Therapeutics in a research note on Thursday, December 12th. One equities research analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Axsome Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $147.13.

Axsome Therapeutics Price Performance

AXSM opened at $131.68 on Tuesday. The company has a debt-to-equity ratio of 1.97, a quick ratio of 2.37 and a current ratio of 2.44. Axsome Therapeutics has a 52-week low of $64.11 and a 52-week high of $134.18. The stock has a market capitalization of $6.38 billion, a PE ratio of -20.17 and a beta of 1.05. The stock’s 50 day moving average price is $96.55 and its 200-day moving average price is $92.67.

Axsome Therapeutics (NASDAQ:AXSM) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($1.34) earnings per share for the quarter, topping the consensus estimate of ($1.38) by $0.04. The company had revenue of $104.76 million for the quarter, compared to analysts’ expectations of $98.71 million. Axsome Therapeutics had a negative return on equity of 158.36% and a negative net margin of 91.87%. During the same period in the prior year, the firm earned ($1.32) earnings per share. On average, equities research analysts predict that Axsome Therapeutics will post -4.7 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Pitcairn Co. lifted its holdings in shares of Axsome Therapeutics by 3.4% during the fourth quarter. Pitcairn Co. now owns 4,562 shares of the company’s stock valued at $386,000 after purchasing an additional 148 shares in the last quarter. Meridian Wealth Management LLC lifted its holdings in shares of Axsome Therapeutics by 0.7% during the fourth quarter. Meridian Wealth Management LLC now owns 21,171 shares of the company’s stock valued at $1,791,000 after purchasing an additional 150 shares in the last quarter. Ameritas Investment Partners Inc. lifted its holdings in shares of Axsome Therapeutics by 4.4% during the fourth quarter. Ameritas Investment Partners Inc. now owns 3,852 shares of the company’s stock valued at $326,000 after purchasing an additional 162 shares in the last quarter. Arizona State Retirement System lifted its holdings in shares of Axsome Therapeutics by 1.8% during the fourth quarter. Arizona State Retirement System now owns 9,054 shares of the company’s stock valued at $766,000 after purchasing an additional 164 shares in the last quarter. Finally, Intrust Bank NA lifted its holdings in Axsome Therapeutics by 6.9% in the fourth quarter. Intrust Bank NA now owns 2,823 shares of the company’s stock valued at $239,000 after acquiring an additional 183 shares during the period. 81.49% of the stock is owned by institutional investors.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.